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Although the antibacterial action of sulfonamide  compounds upon certain 
pathogenic microorganisms  is  now generally  recognized,  the effect  of  these 
drugs upon the immunological response of the animal or human host has not 
been  completely elucidated.  In view  of  the  value  of sulfonamides  in  the 
therapy of pneumonia and other diseases caused by pneumococci and because 
of the essential contribution of immunity to recovery from such infections, it 
seemed desirable  to investigate further the action of sulfapyridine upon the 
immune processes. 
In response  to the antigenic stimulus of pneumococcus the tissues  of man 
and certain animals are capable  of elaborating type specific antibodies which 
circulate  in the blood and can be determined by the appropriate techniques. 
In experimental animals it is also possible to recognize the occurrence of active 
immunity as indicated by increased resistance  to homologous infection which 
may be present before and may persist after the period when circulating anti- 
bodies are detectable.  In the process of spontaneous recovery from pneumo- 
coccal infection  disposal  of the invading microorganisms  by the phagocytic 
ceils cannot be accomplished  without the development of a  specific immune 
response. 
The sulfonamide compounds exert a direct bacteriostatic effect upon various 
microorganisms.  For  these  drugs  to  be  effective  therapeutically, however, 
the participation of specific humoral and cellular  reactions of the host are 
essential  requirements.  The question of whether, in addition to their direct 
actions upon the bacteria, these compounds may not also exert an effect upon 
the defense mechanism of a host has been subjected to both experimental and 
clinical investigation.  It has been  demonstrated in mice injected intraperi- 
tonally with pneumococci that the suffonamide drugs do not affect the mobili- 
zation or activity of the phagocytic cells (1,  4).  Although no evidence  has 
been produced to show that these drugs stimulate or accelerate  the process of 
antibody formation, the assumption that they exert no effect on the immune 
mechanism has not been  unreservedly accepted. 
In 1937 Buttle  (2) observed that mice after recovery from infection with Pneu- 
mococeus Type  I  following treatment  with the  benzylidene Schiff's Base of 4:4' 
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diaminodiphenylsulfone  were  immune  to  reinfection  with  organisms  of  the 
homologous type.  In the following year Whitby  (3)  confirmed this observation in 
mice treated with sulfapyridine.  McIntosh and Whitby (4) found that at the end 
of 1 week mice which had  survived  10,000  lethal  doses of Pneumococcus Type I 
after oral treatment with sulfapyridine were completely immune to reinfection with 
a  million fatal doses of pneumococci of the homologous type.  This immunity was 
related quantitatively to the infective dose and was type specific.  An inocuhm of 
1 million heat-killed pneumococci stimulated in vaccinated mice a degree of immunity 
comparable to that induced in mice following recovery under drug therapy from an 
otherwise fatal infection with 10,000 living pneumococci.  In the latter instance the 
surviving animals on reinoculation  were immune to an amount of virulent culture 
100-fold  greater  than  that  used  in  the  primary  infection.  The  active  immunity 
induced by vaccination or resulting from infection was demonstrable within 3 days. 
By the 4th or 5th day immunity was usually solid,  and on the latter day the sera 
conferred passive  protection  on other mice.  In the sera  of mice immunized with 
Eberthella typhosa agghtinins  were demonstrable  by the 3rd day and increased in 
titer between the 4th and 7th days irrespective of whether or not sulfanilamide had 
been administered.  These authors concluded that  "the administration  of sulphon- 
amide drugs has no stimulating action on the body defenses,  nor does such administra- 
tion affect the quality, quantity, or speed of production of recognized specific anti- 
bodies."  Experimental confirmation of Whitby's observation was reported in 1939 
by CaUerio  (5)  and MacLeod (6).  MacLeod compared the survival rate following 
sulfapyridine  therapy  with  the immune  response in  untreated  animals,  employing 
Pneumococcus Type I, a  good antigen,  and  Pneumococcus Type III, a  relatively 
poor antigen.  He found that in mice infected with 10  -2 cc. of a virulent culture of 
Pneumococcus Type I  and treated with sulfapyridine, 95 to 100 per cent survived, 
whereas in mice similarly treated but infected with Type III pneumococci less than 
10 per cent survived.  In two groups of untreated mice immunized respectively with 
comparable doses of heat-killed pneumococci of Types I and III and infected 5 days 
later  with  1,000  fatal  doses of a  virulent  culture of the corresponding type, 95  to 
100 per cent of those in the Type I  group were immune while none of the Type III 
mice survived.  An apparent correlation was observed not only between the survival 
rate and the relative antigenicity of the respective  types of pneumococci, but  also 
between the differences  in the time required for the development of antibodies and 
the length of time during which it was necessary to continue sulfapyridine treatment. 
Larson, Bieter,  and Levine  (7,  8)  demonstrated that rabbits  which recovered from 
intradermal  infection  with  Pneumococcus Type  II following treatment  with  sulf- 
apyridine were highly resistant to reinfection with the homologous type of organism 
30 or more days later. 
In the sera of patients with pneumococcal pneumonia the appearance of type 
specific antibodies at or about the time of spontaneous recovery is a well recog- 
nized phenomenon.  However, in patients treated with sulfonamide drugs the 
appearance of these antibodies does not necessarily coincide with the deferves- 
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Edwards, Kirch~r, and Thompson (9) tested 26 pneumonia patients treated with 
sulfapyridine  for the development of dermal reactions  to homologous type specific 
capsular polysaccharide as well as for the presence in their sera of type specific  ag- 
glutinins.  They concluded from the results of their observations that the immune 
responses which occur naturally in the course of untreated pneumonia are not affected 
by drug therapy. 
Wood and  Long (10)  demonstrated  specific  protective antibodies  in  the  sera  of 
10 out  of 12  patients  with  pneumococcal pneumonia  who were  treated  with  sulf- 
apyridine.  They concluded  that  the  antibody  response  in  patients  treated  with 
sulfapyridine is similar to that observed in untreated patients. 
Finland,  Spring,  and Lowell (11)  studied  the bactericidal  power of whole blood 
as well as the development of homologous type specific  agglutinins and mouse pro- 
tective antibodies in the sera of a large number of patients with pneumococcal pneu- 
monia treated with sulfapyridine.  These investigators reported that mouse protec- 
tive  antibodies  and agglutinins  were  rarely demonstrable  in patients'  blood before 
the 6th or 7th day although defervescence frequently occurred earlier.  They con- 
cluded that the antibody response in patients  treated  with sulfapyridine  was com- 
parable in all respects to that observed in spontaneous recovery. 
Fox, Rosi, and Winters  (12)  determined the time of appearance of specific  anti- 
bodies in the sera of 50 adult patients  treated with sulfapyridine.  In all patients 
with  proven pneumococcal pneumonia  type specific  agglutinins  were demonstrable 
in  the blood at  some time  in  the  course of illness.  These  same authors  reported 
subsequently  (13)  that in a  larger series  90 per cent of the patients developed type 
specific  agglutinins by the end of the 2nd week of illness  and  that  50 per cent of 
those tested gave true positive skin reactions to the homologous type specific polysac- 
charide. 
Kneeland and Mullikin (14) tested the sera of 19 patients with pneumonia who were 
treated with sulfapyridine.  They observed that positive precipitin reactions to the 
homologous capsular polysaccharide appeared in the sera of only four of their patients 
upon recovery.  In a subsequent paper these authors (15) reported that type specific 
precipitins were detectable in the sera of only 8 of 30 sulfapyridine-treated patients 
as compared with 16 of 21 patients treated with sulfathiazole.  They suggested that 
sulfapyridine by its action upon the invading microorganism diminishes the stimulus 
to antibody formation, whereas sulfathiazole, which they considered a less powerful 
bactericidal agent, exerts this effect to a lesser  degree. 
Bukantz and de Gara (16) demonstrated the presence of homologous type specific 
precipitins during recovery in the sera of nineteen of sixty patients with pneumonia 
who were treated with sulfapyridine. 
In the  animal  experiments  thus  far  reported,  with  the  exception  of those 
of McIntosh and Whitby, tests for resistance  to homologous reinfection have 
been made at a time when immunity had reached or passed the peak of maximal 
response.  In clinical studies the detection of circulating type specific antibody 
is necessarily limited  by the methods which can be employed.  The free cir- 
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sent an excess over the amount actually required for the ini~ation of recovery, 
except  in  those  instances  in  which  a  severe infection  overwhelms the  total 
defense reactions of the patient.  The results obtained by serological methods 
represent the summation of so many interrelated factors that any direct effect 
of  sulfonamide  therapy  upon  the  specific  immune  response  is  necessarily 
obscured. 
The present  study was undertaken  in  order  to  determine  whether  or not 
the administration of a sulfonamide drug has a direct effect upon the develop- 
ment of immunity and to compare the relative sensitivity of various techniques 
used in measuring immunity, such as tests of active resistance to reinfection 
and the serological methods for determining the presence of circulating type 
specific antibodies.  In order  to  standardize  conditions  as much as possible 
it seemed advisable to concentrate attention upon the immune response to a 
potent  antigenic  stimulus  during  the  early stages.  For  this  purpose  Pneu- 
mococcus Type I  was selected as the  test organism, the rabbit as a suitable 
animal host, and sulfapyridine as a  representative sulfonamide drug.  These 
experimental conditions provided an opportunity to employ a  highly virulent 
organism with  potent  antigenic  capacity,  an  an~mnl  at  once  susceptible  to 
infection with the organism and readily immunized by it, and a  chemothera- 
peutic agent highly effective against the organism while not excessively toxic 
for the host. 
EXPERIMENTAL 
Rabbits  were  given  intravenously  a  single  immunizing  injection  of  heat-killed 
Pneumococcus  Type  I.  Approximately half  of  the  vaccinated  animals  received 
sulfapyridine.  Administration of the drug was started prior to vaccination, and was 
continued  during  the period when immunity was developing.  The drug  was dis- 
continued before testing for active immunity by intradermal inoculation  withPneu- 
mococcus Type I. 
Comparable groups of rabbits which had and which had not received sulfapyridine 
were injected intradermaUy with virulent Pneumococcus Type I, 48, 72, and 96 hours 
after vaccination.  The immunizing injection was given to the respective series  of 
animals on successive days so that all of the vaccinated rabbits in  each experiment 
could be infected simultaneously. 
The degree of immune response which  had developed 48,  72, and 96 hours after 
vaccination was estimated in the sulfapyridine-"treated" and  "untreated" rabbits  1 
on the basis of their resistance to intradermal infection as well as by the presence 
1 For convenience  the terms "treated" and "untreated" will hereafter be used to 
designate respectively those rabbits which received sulfapyridine and those to which 
no drug was given.  It should be emphasized, however, that in the "treated" animals 
administration  of sulfapyridine was in  each instance  discontinued  24  to  36  hours 
prior to infection and that none of the rabbits received chemotherapy following the 
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in their sera of circulating type specific precipitins, agglutinins and mouse protective 
antibodies.  For these determinations blood was drawn from  each rabbit prior to 
vaccination and  at  appropriate intervals thereafter up  to  the time of intradermal 
infection. 
Culture.--A virulent strain of Pneumococcus Type I  (S V-I) was used both for 
preparing the vaccines and for intradermal injection.  The virulence of this strain 
was enhanced and maintained by frequent passage in normal rabbits so that 0.2 cc. 
of a 1/500,000 dilution produced a fatal infection when injected intmdermally. 
Preparation of Vaccines.--The organisms from an 8 to 10 hour plain broth culture 
of Pneumococcus Type I  were collected by centrifugation and resuspended in physi- 
ological salt solution equivalent in volume to 1/10 that of the original culture.  The 
organisms were immediately killed by heating the bacterial suspension at 60°C. for 
30 minutes in a water bath and then cultured to control sterility.  A freshly prepared 
vaccine was used in each experiment.  During the 48 hour period of use the vaccines 
were stored in the ice box and in all instances the bacterial cells retained their Gram- 
positive character. 
Immunization.--"ChinchiUa"  rabbits weighing in the neighborhood of 2,000  gm., 
with a maximum variation of 1,560  to 2,500  gm. were kept under observation for a 
period of at least one week before use.  Immunization was carried out by giving each 
rabbit a single intravenous iniection of 1.0 cc. of vaccine corresponding to 10.0 cc. of 
original culture. 
Sulfapyridine  Administration.--Tablets  of  sulfapyridine  (0.5  gin.  Merck)  were 
triturated in a mortar with 0.75 per cent solution of gum tragacanth so that 4.0 cc. 
of the resulting suspension contained 0.5  gin. of sulfapyridine.  The drug was ad- 
ministered by stomach tube in doses of 0.5 gm., the 4.0 cc. of suspension being followed 
immediately by an equal volume of water to wash out the tube and insure passage 
of the whole amount into the stomach.  Administration was begun prior to immuniza- 
tion, continued at intervals of 8 to 12 hours for approximately three days, and dis- 
continued 24 to 36 hours before infecting the animals intradermally.  The total dose 
of sulfapyridine given to each animal was 4.5 gin. with the exception of four rabbits 
which received reduced dosage because of toxic symptoms.  Blood for sulfapyridine 
determinations was drawn at daily intervals during and after the course of drug ad- 
ministration  until  iust  prior  to  intradermal  infection.  The  determinations  were 
made according to the technique of Bratton and Marshall (17)  employing a  photo- 
electric colorimeter. 
Determination  of Type Specific Immunity  by  Means  of Intradermal  Infecthm.-- 
At intervals of 48, 72, and 96 hours after injection of immunizing antigen, both the 
sulfapyridine treated  and  untreated  groups  of  rabbits together with an  adequate 
number of normal control animals were infected intradermally with a virulent culture 
of Pneumococcus Type I  according to the method of Goodner (18).  The infective 
dose, 0.2 cc. of a 1:5,000 dilution of an 8 to 10 hour blood broth culture, was invariably 
fatal for the controls. 
The  degree of immunity was estimated by comparing the clinical course of the 
experimental intradermal  infection  in  the  immunized  and  control  animals.  The 
observations included rectal temperatures twice daily, the severity and progression 
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daily from the marginal ear veins.  Animals  which died were examined at autopsy 
and cultures were made of the heart's blood. 
Determination  of  Circulating  Antibodies.  Precipitins.--Precipitin  tests  were 
carried out using 0.3 cc. respectively of undiluted rabbit serum and a 1:25,000 dilution 
of the acetylated pneumococcus Type I  capsular polysaccharide.  After thorough 
mixing of the contents, the tubes were incubated at 37°C. for 2 hours,  refrigerated 
overnight, and read the following morning. 
Agglutinins.--Tests  for type  specific  agglutinins  were  carried  out  using  serial 
dilutions  of each serum.  Formalin-killed cells of Pneumococcus  Type I, suspended 
in  a  volume of  saline  equal  to that  of  the original  culture were  employed.  To 
0.3  cc. of  the serum  dilutions,  0.3  cc.  of antigen  was  added  and  after  thorough 
mixing the tubes were incubated at 37°C., refrigerated overnight and read the fol- 
lowing morning. 
Mouse  Protective Antibodles.--The  sera  of rabbits  before immunization  and  at 
intervals of 48, 72, or 96 hours thereafter were tested in mice for protective antibodies 
by titrating dilutions of culture against a constant amount of serum. 
The cultures of Pneumococcus Type I (S V-I) used in protection tests were of such 
virulence that the intraperitoneal injection of 10  -s cc. invariably proved fatal.  The 
protection test was considered  negative if 0.2  cc. of serum failed to protect 2 of 3 
mice against 10  -6 cc. of culture.  Sera of rabbits which afforded protection to mice 
infected with 10  -6 cc. (100 ~.L.D.) of culture were also tested against 10  -5 cc. (1000 
M.L.D.).  Amounts of culture greater than this were not used. 
Blood Levels of Free and A cetylated Sulfapyridine.--Blood  drawn at intervals 
during  the  period  of sulfapyridine  administration  indicated  satisfactory ab- 
sorption of the drug.  The blood levels of free and acetylated sulfapyridine, 
however, varied greatly in different animals under the same conditions.  Dur- 
ing the period of administration the highest concentration of free drug noted 
was 15.0 nag. per cent, the lowest 0.5 rag. per cent.  The highest concentration 
of the acetylated compound was 71.2 mg. per cent, the lowest 4.3 mg. per cent. 
Although  the  blood level of free sulfapyridine dropped  fairly rapidly in  the 
interval  between  doses  and  after  administration  was  discontinued,  the 
acetylated form was eliminated much more slowly.  In order that there should 
be little or no sulfapyridine remaining in the blood at the time of intradermal 
infection it was found necessary to discontinue administration of the drug 24 
to 36 hours prior to infection.  Determinations made 24 hours before intra- 
dermal infection showed that only 9 of the 34 animals still had free circulating 
sulfapyridine, although at this time the blood of all of the 22 rabbits tested for 
the  acetylated  compound  showed  its  presence in  amounts  ranging  from 1.3 
to 71.2  rag. per cent. 
Determinations  made  immediately before  infection  upon  the  blood  of 30 
immunized rabbits which  received sulfapyridine  showed the presence  of the 
free drug in 3 instances.  The blood of only one of these animals contained a 
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compound was present in the blood of 11 out of 26 rabbits immediately before 
infection.  The levels varied between 0.5  mg.  and 5.7  rag. per cent.  That 
these residual amounts of sulfapyridine remaining in the blood at the time of 
intradermal infection exerted no significant mitigating effect upon the course 
of the disease is indicated by the following observations.  Sulfapyridine was 
present at the time of intradermal infection in the blood of three Of the four 
treated  animals  which  died.  Furthermore,  the  fatal  course  of  infection in 
four sulfapyridine treated rabbits which were not immunized, was essentially 
the same as that in the normal controls.  Crystals of acetylated sulfapyridine 
were found at autopsy in the bladder and renal pelves of two rabbits which 
developed  overwhelming bacteremia. 
Toxic  Effects of Sulfapyridine.--Almost  all  of  the  rabbits which  received 
sulfapyridine showed some evidence of intoxication during the course of drug 
administration.  This was manifested by varying degrees of anorexia, weak- 
ness, and loss of weight.  Sulfapyridine intoxication may have been a  con- 
tributory factor in the death of one rabbit which was infected 72 hours after 
immunization and died on the 4th day after a mild illness unaccompanied by 
bacteremia.  Postmortem examination revealed a  loss of 300 gm.  in weight, 
a minimal skin lesion showing evidence of healing and no gross abnormalities 
of  the  organs.  Analysis  of  the  bladder  urine  disclosed  the  presence  of 
acetylated sulfapyridine in a concentration of 2.5 mg. per cent. 
It seems evident that  the amount of drug used in these experiments was 
about the maximum that could be tolerated by the animals over the period of 
administration. 
Effects of Intravenous Injection  of Pneumococcal Vaccines.--The intravenous 
injection of heat-killed Pneumococcus Type I  was frequently followed by an 
immediate but  transient  elevation of temperature.  No  other untoward re- 
actions were noted.  The variations of the immune response in sulfapyridine 
treated and untreated animals at  different intervals following immunization 
are considered later in detail. 
Characteristics of the Disease Produced by Intradermal Infection.--The disease 
produced  in  rabbits  by the  intradermal  injection of Pneumococcus Type I 
has been thoroughly described by Goodner (18, 19).  The cotrrse of the illness 
in the 26 control animals corresponded closely to his description.  The disease 
was characterized by high sustained fever, extensive dermal lesions, progressive 
bacteremia, and an invariably fatal termination within 6 days.  In immunized 
rabbits modifications of these findings were progressively more in evidence as 
the interval between immunization and infection was increased.  As a  basis 
for the estimation of active immunity, the effects of infection at different in- 
tervals after immunization in rabbits which received sulfapyridine are com- 
pared with the reactions of animals to which no drug was given.  These data 
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T~xT-FIG. 1.  Characteristics of the disease produced by intradermal infection with 
Pneumococcus Type I in rabbits previously immunized with a heat-killed suspension 
of organisms of the homologous type.  Immunization was  carried out by a  single 
intravenous injection of a suspension of heat-killed Pneumococcus Type I equivalent 
to 10 cc. of original culture.  Intradermal infection was initiated by the injection of 
0.2 cc. of a 1:5000 dilution of an 8 to 10 hours rabbit blood broth culture of virulent 
Pneumococcus Type I.  Solid black shading indicates the number of  days during 
which a  rabbit's temperature was  elevated to  104  ° or above.  Absence of shading 
indicates absence of fever.  Plus signs represent the  occurrence of  dermal lesions 
graded in severity from +  to represent a minimal lesion to + +  + +  indicating  one of 
maximal intensity.  Minus sign indicates that no lesion developed.  Cross hatching 
represents the  incidence and duration of  bacteremia.  The  small numbers in the 
cross hatched areas indicate the bacterial colony counts per cubic centimeter.  Cul- 
tures of the blood which proved sterile are indicated by the symbol 0.  D  indicates 
animals which died, and with but one exception is placed so as to designate the day of 
death.  Rabbit 7-11 died on the llth day with persisting bacteremia. EDWARD  C.  CURNEN  AND  COLIN  M.  M'AeLEOD  85 
The criteria for these comparisons  include  the incidence  and duration of 
fever,  the occurrence  and severity of the lesions, the degree and duration of 
bacteremia, as well as the number of fatalities and the time of their occurrence. 
Temperatures of 104°F. or above were considered abnormal.  The degree of 
temperature elevation is not included in this report since in most instances high 
fever continued until the time of death or recovery.  The severity of lesions 
has been designated by the symbols +  to + + + +, to represent the gradations 
of dermal involvement varying from a  small  circumscribed  tuberculin-like 
reaction to an extensive area of dependent inflammatory  edema with ecchymosis 
and necrosis.  The most severe reactions were usually observed in the unvac- 
cinated  control  animals,  but  not  invariably, since  several  died before  the 
lesions appeared to be fully developed.  Evidences of incipient healing of the 
dermal infection usually paralleled other indications of recovery.  The rate of 
healing seemed  to depend upon the extent and severity of the lesions.  The 
outcome of the infection, however, could not be predicted from the severity of 
the local inflammatory  process, for many of the animals infected 48 hours after 
vaccination had lesions of maximal intensity but ultimately survived. 
In all of the control animals,  and with but two exceptions  among the 23 
vaccinated rabbits which developed bacteremia, cultures of the blood taken 24 
hours after infection yielded growth of Pneumococcus Type I.  In most of the 
vaccinated rabbits, notably those with low initial colony counts, cultures of the 
blood became sterile coincidentally with other evidences of recovery,  whereas 
in some of the vaccinated and in all of the unvaccinated rabbits, bacteremia 
persisted  and progressively increased until the time of death.  From seven of 
the eight fatalities among the 62  immunized rabbits, Pneumococcus  Type I 
was isolated in cultures of the blood  taken during life or at autopsy.  The 
single  exception  was the  rabbit  mentioned above which may have  died of 
sulfapyridine intoxication. 
Non-Immunized Rabbits.--In the 26 control animals which received no sulfa- 
pyridine the  infection followed a  uniformly fatal course.  Included in  this 
number are those rabbits which received  1/10 or 1/100  of the inoculum em- 
ployed routinely in infecting the vaccinated animals.  High fever persisted 
usually until the time of death and the lesions were characteristically of maxi- 
mal intensity.  Cultures of the blood  taken 24 hours after infection yielded 
from three to myriad colonies per cubic centimeter, and in every instance over- 
whelming blood stream invasion occurred prior to the invariably fatal termina- 
tion within 6 days.  In the four unvaccinated rabbits which received  sulfa- 
pyridine the course and termination of the disease were identical. 
Rabbits  Infected  48 Hours after Immunization.--(Text-fig.  1.)  Ten rabbits 
which received preliminary administration of sulfapyridine and ten which did 
not were infected 48 hours after immunization.  As shown in Text-fig.  1 all 
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fever which lasted from 1 to 5  days,  averaging about 3  days in  the febrile 
animals of both groups.  The lesions varied in severity from ++  to ++++ 
in both groups.  On the whole the intensity of the lesions was perhaps a little 
less severe in the treated than in the untreated animals.  However, eight of 
the rabbits in each group had positive blood cultures 24 hours after infection. 
Although the severity of illness in most of the rabbits was such that  death 
seemed imminent over a  period of several days, only two animals from each 
group ultimately succumbed,  three within 4  days and one on the  11th day 
following persistent bacteremia. 
Rabbits  Infected  72  Hours  after  Immunization.--(Text-fig.  1.)  In the  ten 
treated and ten untreated rabbits which were infected 72 hours after immuni- 
zation the manifestations of infection were considerably less than in the com- 
parable groups of animals infected 24 hours earlier.  Although fever occurred 
in every instance it was of shorter duration, averaging about  1{ days in the 
untreated and  2½  days in  the  treated animals.  The severity of the  lesions 
was also less intense averaging about +  +  in both groups with extreme varia- 
tions of +  to ++++.  Bacteremia occurred in four of the untreated rabbits 
of which two died, and in three of the treated animals of which one died.  One 
treated rabbit which did not have bacteremia died on the 4th day of illness. 
Rabbits  Infected  96 Hours after Immunization.--(Text-fig.  1.)  Half of the 
rabbits  infected 96 hours after immunization,  whether treated or untreated, 
seemed to be unaffected by the same inoculum of Pneumococcus Type I  pro- 
ducing severe disease in animals infected after shorter intervals.  Only four of 
twelve  untreated  and  three  of  ten  treated  rabbits  developed  fever.  The 
average duration was 2 days in each group.  Lesions occurred in five animals 
of each group and were for the most part of minimal intensity with individual 
variations in severity to +++.  None of these animals developed bactermia 
and all survived. 
Active Immune Response at Different  Intervals  Following Immunization.--In 
the immunized rabbits manifestations of the disease produced by intradermal 
infection were progressively less severe as the interval between immunization 
and infection was increased.  The enhancement of resistance to infection in 
animals which had not received sulfapyridine could be explained only on the 
basis of an immune response to vaccination.  Likewise, in the animals which 
received sulfapyridine there was  no evidence to contradict this assumption. 
In order to compare the degree of active immunity in the respective treated 
and untreated groups of animals,  and thereby determine whether or not the 
response in treated animals was affected by drug administration, a  modifica- 
tion of the  classification devised by Goodner (19)  has been employed.  Im- 
munized rabbits which showed all the characteristics of the disease invariably 
noted in the controls, including a  fatal termination, were considered to have 
no  immunity.  Those  which  showed  no  manifestations  of  disease  were  re- EDWARD  C. CITRNEN  AND  COLIN M. MAcLEOD  87 
garded  as  completely immune  to  the  infecting dose  employed.  Grades  of 
immunity  between these extremes have been observed as indicated in Text-fig. 
2.  With only two exceptions each rabbit could be readily classified in one of 
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2.  Active  immunity  in  rabbits  at  different intervals  following  ira- 
munization. 
Grade of immunity 
0  =  no immunity 
I- 
II= 
III= 
IV  =  complete immunity 
Corresponding characterlsa~s of disease 
Fever, lesion, bacteremia, and death. 
Fever, lesion, bacteremia, survived. 
Fever and lesion, no bacteremia, survived. 
Minimal lesion, no fever, no bacteremia, survived. 
No evidence of disease, survived. 
All of the control animals had 0 immunity. 
~Only 2  animals  did not fit readily into  these  categories:  (1)  moderate lesion 
and bacteremia, no fever, survived; (2) fever and lesion, no bacteremia, died. 
the  designated  categories.  Since  all  of  the  unvaccinated  control  animals 
showed no immunity they have not been included in the chart. 
It is evident that as early as 48 hours after immunization most of the treated 
and untreated rabbits had some degree of resistance to intradermal infection. 
This is indicated chiefly by the fact that 80 per cent of the animals in both 
groups survived.  The immunity was of a  low order, however.  60 per cent 88  SUL]~APYRIDINE  AND  PNEUMOCOCCUS  E~TMUNITY IN  RABBITS 
of the surviving animals of both groups had initial bacteremia, and their degree 
of immunity has therefore been classified as of grade I. 
When infection was deferred until 72 hours after vaccination there was an 
appreciable enhancement of the active immune response.  80 per cent of these 
animals, both treated and untreated, survived.  60 per cent of the surviving 
rabbits  in both groups  did not develop bacteremia and their degree of im- 
munity is classified as of grade IL 
When rabbits were infected 96  hours after vaccination, bacteremia never 
occurred and little or no disease resulted.  Approximately half of the animals, 
50 per cent in the sulfapyridine treated and 58 per cent of the untreated group 
showed  complete immunity classified  as  of grade  IV.  The remainder also 
showed a pronounced immune response estimated as of grades II or III. 
Although differences in the active immune response of animals infected at 
varying intervals following immunization are quite striking, comparison of the 
corresponding sulfapyridine treated and untreated groups shows no such dis- 
parity.  At each interval following vaccination the distribution of treated and 
untreated animals according to their relative grade of immunity to intradermal 
infection is practically identical.  It is quite evident that under the conditions 
of the experiment sulfapyridine exerted no appreciable effect upon the early 
development of active immunity.  In an additional experiment rabbits failed 
to show any resistance to intradermal infection with virulent Pneumococcus 
Type 1 48 hours after preliminary vaccination with a suspension of heat-killed 
"rough" organisms derived from Pneumococcus Type II.  This indicates that 
the early immune response to homologous vaccination is type specific in nature 
and not the result of a non-specific enhancement of resistance. 
Occurrence of Demonstrable Circulating Antibodies in the Sera of Immunized 
Rabbits.--Sera  obtained  from  rabbits  prior  to  injection  of vaccine  and  at 
intervals of 48,  72,  and 96 hours thereafter were tested for circulating type 
specific precipitins,  agglutinins,  and  mouse protective antibodies.  Sera  ob- 
tained from animals used for determinations of active resistance to intradermal 
infection as well as sera from a number of similarly vaccinated but uninfected 
rabbits  were  examined.  The  results  of  these  observations  are  shown  in 
Text-fig. 3. 
Tests for circulating antibody in the sera of vaccinated rabbits which did 
not receive sulfapyridine were, with but one exception, negative until 96 hours 
after the intravenous immunization with Pneumococcus Type I.  The serum 
of  one  rabbit  obtained  72  hours  after vaccination,  protected mice  against 
10  -s cc. of pneumococcus culture whereas serum from the same animal 24 hours 
earlier conferred no protection.  This rabbit was not one of those tested for 
resistance to intradermal infection.  Of the sera obtained from 22 rabbits 96 
hours after immunization, 18 (82 per cent) protected mice against an infecting 
dose of 10  --e cc.  (100 M.L.D.) and all but one of them against  10  -5 cc.  (1000 EDWARD  C. CURNEN  AND  COLIN M. MACLEOD  89 
M.L.D.) Of  pneumococcus  culture.  In  thirteen  (59  per  cent)  of  these  sera 
type specific agglutinins were also detectable, but in low titer of 1:2 or 1:4. 
Type specific precipitins were observed in but two (17 per cent) of the twelve 
sera tested and in these instances the reactions were only faintly positive. 
Similarly, circulating antibody could not be detected until 96 hours after 
vaccination in any of the sera from rabbits which had received sulfapyridine. 
Of the  fourteen sera  tested after this interval twelve  (86 per  cent)  showed 
mouse protective antibodies.  In all but one instance the mice were protected 
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TExT-Fro. 3.  Circulating  antibodies in the sera of rabbits at different  intervals 
following immunization.  *P indicates the presence of type specific precipitins with 
the acetylated polysaccharide of Pneumococcus  Type I  in a  dilution of 1:50,000. 
A indicates the presence of type specific agglutinins  of Pneumococcus Type I.  MP 
indicates the protection of mice against an intraperitoneal injection of at least 10  -ecc. 
virulent Pneumococcus Type I by 0.2 cc. of serum.  ~To these totals may be added 
the number of those sera which showed no antibody 72 hours after vaccination and 
therefore presumably contained no demonstrable antibody 24 hours earlier. 
against  10  -~ cc.  (1000 M.ED.) of a  virulent culture of Pneumococcus Type I. 
Six (43 per cent) of the fourteen sera contained type specific agglutinins.  The 
highest titer was  1:8 in one instance.  Positive precipitin reactions with the 
type specific capsular polysaccharide noted in only three (33 per cent) of the 
ten sera tested were faint and equivocal. 
From these observations it is seen that tests for circulating antibodies usually 
did not reveal the development of immunity until 4  days after intravenous 
injection of vaccine and at least 2 days after active resistance to intradermal 
infection was  demonstrable.  Antibodies could be detected only in the sera 
of rabbits which had a relatively high degree of active immunity as indicated 
by resistance to intradermal infection.  The findings are practically identical 
in the treated and untreated groups of animals indicating that the early de- 90  SULFAPYRIDINE  AND  PNEUMOCOCCUS  FM'~UNITY  IN"  RABBITS 
velopment of circulating antibodies as well as the early development of active 
resistance is not influenced by the administration of sulfapyridine. 
DISCUSSION 
It is evident from the experimental data that the administration of sulfa- 
pyridine has no appreciable effect upon the immune response in rabbits follow- 
ing a  single intravenous injection of heat-k~led suspension of Pneumococcus 
Type  I. 
Of particular significance is the fact that active immunity, as indicated by 
resistance to intradermal infection, was present 48 hours before any appreciable 
immune response  could  be  detected  by  tests  for  circulating antibody.  96 
hours after vaccination, when antibodies were first demonstrable in the sera, 
all of the animals tested were almost solidly immune to intradermal infection. 
Of the techniques employed for the determination of circulating antibody, 
the mouse protection test was found to be the most sensitive, revealing the 
presence of antibody in approximately twice as many instances as did the test 
for agglutinins or precipitins. 
The precipitin reaction,  although an exquisitely sensitive method for the 
detection of minute amounts of capsular polysaccharide, is less satisfactory 
than the mouse protection and agglutination tests for the purpose of demon- 
strating small amounts of antibody.  As the precipitate which forms the basis 
of this reaction is composed almost entirely of antibody, small amounts of 
antibody may fail to produce a visible reaction with varying dilutions of antigen 
although in the presence of adequate antibody the reaction with antigen in 
dilution as high as 1 : 5,000,000  may yield a visible precipitate.  Furthermore, 
when  used  to  test  the  sera  of patients  with pneumococcal pneumonia  the 
precipitin reaction introduces another possible factor of error.  If the prepara- 
tion of capsular polysaccharide employed is contaminated with even a  trace 
of the pneumococcus C polysaccharide the reaction of the latter substance with 
the  C  reactive  protein  of acute phase  serum may be  misinterpreted as  an 
indication of the presence of type specific antibody (20, 21). 
In man studies comparable to those which can be carried out in experimental 
animals are not feasible.  Because of the many variables existing in the patient 
with pneumococcal pneumonia it would be impossible to conclude from the 
failure  to  demonstrate  circulating type specific  antibody that  resistance  to 
infection had not developed or that administration of a sulfonamide drug had 
affected  the  development  of  immunity. 
Either failure to produce sufficient circulating antibody or the removal of 
free  antibody by  combination with  circulating antigen  could  preclude  the 
detection of antibody.  In any event, positive results indicate only that an 
excess  of antibody is present,  whereas  negative results may signify merely 
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Experimental  observations, however, point clearly to the fact that  a  con- 
siderable  type specific  immune  response  to pneumococcus develops rapidly 
and may be adequate to protect against infection in the absence of demonstrable 
circulating  antibody.  Although  the  various  types of pneumococci vary in 
their ability to stimulate antibody formation it seems unlikely that the sulfon- 
amide drugs exert different effects upon this particular  property in different 
types of pneumococcus.  From the present study it appears that the develop- 
ment  of immunity in response to a  specific antigenic  stimulus proceeds ac- 
cording to the effectiveness of the stimulus irrespective of whether sulfapyridine 
has been administered. 
SIY~MARY 
1.  Sulfapyridine,  administered  to rabbits  during  the period of developing 
immunity  after  a  single  intravenous  injection  of heat-killed  Pneumococcus 
Type I, exerted no influence upon the immune response. 
2.  Active  immunity  as  indicated  by increased  resistance  to  homologous 
intradermal infection was present 48 hours after the immunizing  injection and 
2 days before circulating type specific antibodies were detectable. 
3.  Of the serological  techniques employed for the detection of circulating 
antibody the mouse protective test yielded the highest percentage of positive 
results followed in order by tests for type specific agglutinins and precipitins, 
the  latter  being  least  satisfactory  for  the  detection  of  small  amounts  of 
antibody. 
CONCLUSION 
The experimental findings  lend further  support to the view that,  in man, 
effective therapy of pneumococcal infections with sulfonamide drugs is  inti- 
mately associated with the development of active immunity. 
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